Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study offers 'real hope' for C.diff sufferers
Stomach pain
In the US alone, almost 500,000 C.diff infections occurred in 2011, resulting in 29,000 deaths.
Harmless spores of C.diff prevent repeated infection

Giving spores of non-toxic Clostridium difficile (C.diff) by mouth is effective in stopping bouts of C.diff infection, according to a study published in The Journal of American Medical Association.
 
C.diff infection is a type of bacterial infection that affects the digestive system. It most commonly affects those who have been treated with antibiotics.

Symptoms include severe diarrhoea, a high temperature and painful abdominal cramps.

Lead author Dale Gerding, professor of medicine at Loyola University Medical Centre (LUMC), Chicago, said: "Results of this study confirm findings of earlier studies that showed that if we can establish non-toxic C.diff as a resident of the gut of the patient, that we can protect the patient from infection by the toxic strains of C.diff.”

He adds that the results are worthy of further study to confirm that treatment with non-toxic C.diff spores can reduce recurrent C.diff infection and prevent a first episode of C.diff infection in those who are taking any antibiotics and are at high risk of infection.

Dale Gerding and an international team of infectious disease researchers ran trials on 173 adult patients.  Of those assigned non-toxic C.diff in liquid form, 11 per cent experienced a repeat infection within 42 days, compared with 30 per cent of those given a placebo - showing a significant reduction.

Hospital acquired infections, including C.diff, are an increasing problem throughout the world. In the US alone, almost 500,000 C.diff infections occurred in 2011, resulting in 29,000 deaths.

Stuart Johnson, infectious disease specialist at LUMC, said that the study offers 'real hope' for those debilitated by recurring bouts of the infection.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.